EUVIMEDObjevte EUVIMED
MetaanalyseSystematische Übersicht

Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta‐analysis

Daniele Tienforti, Chiara Castellini, Francesca Di Giulio, Maria Totaro, Gilda Dalmazio, Luca Spagnolo, Mario Muselli, Giovanni Corona iD, Marco Giorgio Baroni, Arcangelo Barbonetti iD

Andrology · 2023

DOI: 10.1111/andr.13373 ↗

At a glance

Metaanalyse in Andrology, 2023. Written by Daniele Tienforti and 9 co-authors. Institution: Department of Clinical Medicine, Life, Health and Environmental Sciences, Andrology Unit, University of L'Aquila, L'Aquila, Italy. Major MEDLINE topics: Enclomiphene, Eunuchism, Hypogonadism. Cited 11 times so far (Crossref); 46 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Although selective estrogen receptor modulators have been proposed as a treatment for men with central functional hypogonadism, only a few data have been produced in men with obesity‐related functional androgen deficiency.

Objective

To determine whether and to what extent selective estrogen receptor modulators are an effective and safe therapy in men with obesity‐related functional androgen deficiency. Materials and methods A thorough search of PubMed, Web of Science, Scopus, and Cochrane Library databases was performed to identify studies comparing testosterone levels before and after treatment. Mean differences with 95% coefficient intervals were combined using random effects models. Funnel plot, Egger's test, and trim‐and‐fill analysis were used to assess publication bias.

Results

Seven studies met the inclusion criteria providing information on 292 men with obesity‐related functional androgen deficiency treated with clomiphene citrate (12.5–50 mg daily) or enclomiphene citrate (12.5–25 mg daily) for 1.5–4 months. The pooled estimates indicated a significant increase in testosterone levels both with clomiphene (mean difference: 11.56 nmol/L; 95% coefficient interval: 9.68, 13.43; I 2 = 69%, p for heterogeneity = 0.01) and enclomiphene citrate (mean difference: 7.50 nmol/L; 95% coefficient interval: 6.52, 8.48; I 2 = 4%, p for heterogeneity = 0.37). After the exclusion of one study on severely obese men, who exhibited the highest response rate to clomiphene citrate, the heterogeneity disappeared (mean difference: 10.27 nmol/L; 95% coefficient interval: 9.39, 11.16; I 2 = 0%, p for heterogeneity = 0.66). No publication bias was revealed by Egger's test and trim‐and‐fill analysis. No treatment‐related unexpected findings regarding safety profile were registered. Discussion and conclusion Treatment with clomiphene citrate and enclomiphene citrate may be an effective and safe alternative to testosterone replacement therapy in men with obesity‐related functional androgen deficiency. Further long‐term studies are warranted to define clinical reflections of the selective estrogen receptor modulators‐induced increase in testosterone levels and to better clarify the safety profile.

Subjects

MeSH terms (MEDLINE)

EnclomipheneEunuchismHypogonadismHumansMaleAndrogensClomipheneObesityReceptors, EstrogenSelective Estrogen Receptor ModulatorsTestosteroneEstrogen Receptor alpha

Author keywords

clomipheneenclomiphenehypogonadismmetabolic syndrometestosterone

Substances

AndrogensClomipheneEnclomipheneReceptors, EstrogenSelective Estrogen Receptor ModulatorsTestosteroneESR1 protein, humanEstrogen Receptor alpha

Authors and institutions

  • Department of Clinical Medicine, Life, Health and Environmental Sciences, Andrology Unit, University of L'Aquila, L'Aquila, Italy.
  • Department of Life, Health and Environmental Sciences, Epidemiology Division, University of L'Aquila, L'Aquila, Italy.
  • Endocrinology Section, Maggiore Hospital, Bologna, Italy.
  • Neuroendocrinology and Metabolic Diseases, IRCCS Neuromed, Pozzilli, Italy.

ORCID profiles: Giovanni Corona, Arcangelo Barbonetti

Cite

APA

Tienforti, D., Castellini, C., Di Giulio, F., Totaro, M., Dalmazio, G., Spagnolo, L., Muselli, M., Corona, G., Baroni, M. G., & Barbonetti, A. (2023). Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta‐analysis. Andrology. https://doi.org/10.1111/andr.13373

Vancouver

Tienforti D, Castellini C, Di Giulio F, Totaro M, Dalmazio G, Spagnolo L, et al. Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta‐analysis. Andrology. 2023. doi:10.1111/andr.13373

BibTeX
@article{Tienforti2023,
  author = {Tienforti, Daniele and Castellini, Chiara and Di Giulio, Francesca and Totaro, Maria and Dalmazio, Gilda and Spagnolo, Luca and Muselli, Mario and Corona, Giovanni and Baroni, Marco Giorgio and Barbonetti, Arcangelo},
  title = {Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta‐analysis},
  journal = {Andrology},
  year = {2023},
  doi = {10.1111/andr.13373}
}
Start for free →